March 25, 2020
Pharmaceutical manufacturing facilities in India are deemed an essential service and exempt from the country-wide lockdown. Accordingly, Mylan continues to operate its manufacturing facilities without significant disruption in service to the many patients who rely on Mylan's medicines while simultaneously taking proactive measures to protect the wellbeing of its workforce. We’re continuing to monitor developments closely as the situation continues to evolve.
This statement includes statements that constitute "forward-looking statements," including with regard to Mylan continuing to operate its manufacturing facilities without significant disruption and the situation in India. Because forward-looking statements inherently involve risks and uncertainties, actual future events may differ materially from those expressed or implied by such statements. Factors that could cause or contribute to such differences include, but are not limited to the impact of the COVID-19 pandemic; actions and decisions of healthcare and pharmaceutical regulators in India and elsewhere; changes in healthcare, pharmaceutical or other laws and regulations; other uncertainties and matters beyond the control of management; and the other risks detailed in Mylan's filings with the Securities and Exchange Commission. Mylan undertakes no obligation to update these statements for revisions or changes after the date of this statement.